• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Ispire Technology Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    1/22/25 4:45:26 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $ISPR alert in real time by email
    false 0001948455 0001948455 2025-01-20 2025-01-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): January 20, 2025

     

    Ispire Technology Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-41680   84-5106049
    (State or other jurisdiction of
    incorporation or organization)
      (Commission file number)   (IRS Employer
    Identification No.)

     

    19700 Magellan Drive

    Los Angeles, CA 90502

    (Address of principal executive offices) (Zip Code)

     

    Registrant’s telephone number, including area code: (310) 742-9975

     

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.0001 per share   ISPR   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 8.01 Other Events

     

    On January 20, 2025, the Board of Directors (the “Board”) of Ispire Technology Inc. (the “Company”) authorized and approved a share repurchase program for up to $10 million of the currently outstanding shares of the Company’s common stock over a period of 24 months (the “Repurchase Program”). Under the Repurchase Program, the Company intends to repurchase shares through open market purchases, privately negotiated transactions, block purchases or otherwise in accordance with applicable federal securities laws, including Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

     

    The Board also authorized the Company to enter into written trading plans under Rule 10b5-1 of the Exchange Act.  Adopting a trading plan that satisfies the conditions of Rule 10b5-1 allows a company to repurchase its shares at times when it might otherwise be prevented from doing so due to self-imposed trading blackout periods or pursuant to insider trading laws. Under any Rule 10b5-1 trading plan, the Company’s third-party broker, subject to Securities and Exchange Commission regulations regarding certain price, market, volume and timing constraints, would have authority to purchase the Company’s common stock in accordance with the terms of the plan.  The Company may from time to time enter into Rule 10b5-1 trading plans to facilitate the repurchase of its common stock pursuant to its share repurchase program.

     

    The Company cannot predict when or if it will repurchase any shares of common stock as such stock repurchase program will depend on a number of factors, including constraints specified in any Rule 10b5-1 trading plans, price, general business and market conditions, and alternative investment opportunities. The Repurchase Program may be modified, suspended or discontinued at any time without prior notice. Information regarding share repurchases will be available in the Company’s periodic reports on Form 10-Q and 10-K filed with the Securities and Exchange Commission as required by the applicable rules of the Exchange Act.

     

    On January 22, 2025, the Company issued a press release announcing that the Board has approved a Repurchase Program. The full text of the press release is filed herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

     

    1

     

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d)  Exhibits

     

    The following exhibits are being filed with this Current Report on Form 8-K:

     

    Exhibit No.   Description of Exhibit
    99.1   Press release, dated January 22, 2025, from Ispire Technology Inc.
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    2

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      Ispire Technology Inc.
         
      By: /s/ Michael Wang
        Name:  Michael Wang
        Title: Co-Chief Executive Officer
         
    Dated: January 22, 2025    

     

     

    3

     

    Get the next $ISPR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ISPR

    DatePrice TargetRatingAnalyst
    5/20/2024$11.00Buy
    ROTH MKM
    More analyst ratings

    $ISPR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ispire Highlights Economic Impact of New FDA Guidance on Flavored ENDS Unlocking a $50 Billion Market and Driving Significant Potential Asset Value

    FDA establishes first-ever framework for flavored ENDS, recognizing device level age verification as a regulatory requirementFDA guidance unlocks an estimated $50 billion total addressable market, allowing companies to lawfully transition the 70% illicit flavored vape market into a compliant ecosystemIspire's 40%-owned IKE Tech joint venture is positioned to generate $5 million to $20 million in annual recurring SaaS revenue per customer in the USBased on conservative SaaS metrics, even a limited number of customers could potentially value the IKE joint venture in the hundreds of millions, dramatically increasing Ispire's book valueIspire-backed IKE Tech was first to file component PMTA for

    3/16/26 8:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    IKE Tech Welcomes Landmark FDA Recognition of Device-Level Age Verification in Nicotine Regulation

    New FDA draft guidance formally acknowledges device-embedded age-gating technology in PMTA review for the first time, signalling the important role that technology and innovation can play in addressing youthusage and access to nicotine products.LOS ANGELES, March 16, 2026 /PRNewswire/ -- IKE Tech LLC ("IKE Tech") today welcomed the U.S. Food and Drug Administration's (FDA) draft guidance on Flavored ENDS Premarket Tobacco Product Applications, which formally introduces Device Access Restrictions (DAR) as a consideration in FDA's determination as to whether an ENDS product is Appropriate for the Protection of Public Health (APPH) and continues the Administration's goals of protecting youth he

    3/16/26 8:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. to Participate in the 38th Annual ROTH Conference

    LOS ANGELES, March 11, 2026 /PRNewswire/ -- Ispire Technology Inc. ((ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today announced that Ispire's management team will participate in the 38th Annual ROTH Conference taking place in Dana Point, California from March 22-24, 2026. 38th Annual ROTH ConferenceDate: March 22-24, 2026Location: Dana Point, CaliforniaFireside Chat Details: Monday, March 23, 2026, at 8:00 a.m. PT in Blue-Consumer-Salon 2To schedule a one-on-one meeting with the Company's management team, please

    3/11/26 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    SEC Filings

    View All

    SEC Form 10-Q filed by Ispire Technology Inc.

    10-Q - Ispire Technology Inc. (0001948455) (Filer)

    2/6/26 4:30:49 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-Q filed by Ispire Technology Inc.

    10-Q - Ispire Technology Inc. (0001948455) (Filer)

    11/6/25 4:31:10 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-K filed by Ispire Technology Inc.

    10-K - Ispire Technology Inc. (0001948455) (Filer)

    9/15/25 4:06:16 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Co-Chief Executive Officer Wang Michael Xue bought $11,959 worth of shares (5,000 units at $2.39), increasing direct ownership by 1% to 466,882 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    3/2/26 4:58:37 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Co-Chief Executive Officer Wang Michael Xue bought $18,529 worth of shares (8,000 units at $2.32), increasing direct ownership by 2% to 461,882 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    2/26/26 4:27:49 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on Ispire Technology with a new price target

    ROTH MKM initiated coverage of Ispire Technology with a rating of Buy and set a new price target of $11.00

    5/20/24 7:18:59 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Co-Chief Executive Officer Wang Michael Xue bought $11,959 worth of shares (5,000 units at $2.39), increasing direct ownership by 1% to 466,882 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    3/2/26 4:58:37 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Co-Chief Executive Officer Wang Michael Xue bought $18,529 worth of shares (8,000 units at $2.32), increasing direct ownership by 2% to 461,882 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    2/26/26 4:27:49 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    CLO and Secretary Pryzbyla Steven P. sold $29,592 worth of shares (9,000 units at $3.29), decreasing direct ownership by 2% to 390,664 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    2/17/26 5:53:18 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Leadership Updates

    Live Leadership Updates

    View All

    WM Technology, Inc. Appoints Harry DeMott and Brent Cox to Board of Directors and Announces Executive Employment Arrangement with CFO Susan Echard

    WM Technology, Inc. ("WM Technology" or the "Company") (NASDAQ:MAPS), a leading marketplace and technology solutions provider to the cannabis industry, today announced the appointment of Harry DeMott and Brent Cox to the Company's Board of Directors, effective February 1, 2026. The Company also announced that Susan Echard will continue to serve as Chief Financial Officer, transitioning from a contracted arrangement to employment with the Company, effective January 30, 2026. "We are pleased to welcome Harry and Brent to WM Technology's Board of Directors. They each bring a combination of cannabis industry perspective, technology fluency, and disciplined capital markets experience," said Do

    2/3/26 5:45:00 PM ET
    $ISPR
    $MAPS
    Medicinal Chemicals and Botanical Products
    Health Care
    Computer Software: Prepackaged Software
    Technology

    Ispire-Backed IKE Tech to Spotlight Breakthroughs in Vape Safety and Harm Reduction at World Vape Show Dubai

    President of Ike Tech and SVP of International Nicotine at Ispire, John Patterson, to Join Global Leaders on Industry Innovation Panel LOS ANGELES, June 16, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a global leader in vaporization technology and precision dosing, announced its joint venture IKE Tech LLC ("IKE Tech") will spotlight Ike Tech's blockchain based point of use age-gating and Smart-Tag authentication technologies at the World Vape Show Dubai, June 18–20, 2025. John Patterson, president of Ike Tech and senior vice president of International Nicotine at Ispire, will be featured on a high-level panel titled "Innovations in Consumer Safety

    6/16/25 8:30:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Announces Appointment of Jay Yu as Chief Financial Officer

    Jie "Jay" Yu has a strong track record of excellence in public company accounting, and has served in the role of Vice President of Finance for Ispire since June 2023 Ispire also further streamlines operations by cutting an estimated $3.6 million in annual payroll in May 2025 Ispire expects to also cut up to an additional $6.6 million in annual operating expenses over the next three months, for a total estimated annualized expense reduction of $10.2 million LOS ANGELES, May 15, 2025 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today announced the appointment of Jie "Jay" Yu as the

    5/15/25 4:30:00 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Financials

    Live finance-specific insights

    View All

    Ispire Technology Inc. Reports Financial Results for Fiscal Second Quarter 2026

    Ongoing Focus on Collections Drives 19% Reduction in Net Accounts Receivable since June 30, 2025Cash of $17.6 Million at December 31, 2025  LOS ANGELES, Feb. 6, 2026 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported financial results for the second quarter of fiscal 2026, for the three months ended December 31, 2025. Fiscal Second Quarter 2026 Financial Results Revenue of $20.3 million versus $41.8 million for the second quarter of fiscal 2025.Gross profit

    2/6/26 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Schedules Fiscal Second Quarter 2026 Earnings Conference Call

    LOS ANGELES, Feb. 3, 2026 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a trailblazer in vaping technology and precision dosing, announced today that it will host its earnings conference call at 8:00 am ET on Friday, February 6, 2026, to discuss the Company's financial results for its fiscal second quarter ended December 31, 2025. To listen to the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the "Ispire Technology Call." Date: Friday, February 6, 2026Time: 8:00 am ETDial-In Number

    2/3/26 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Schedules Fiscal First Quarter 2026 Earnings Conference Call

    LOS ANGELES, Nov. 4, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a trailblazer in vaping technology and precision dosing, announced today that it will host its earnings conference call at 8:00 am ET on Thursday, November 6, 2025, to discuss the Company's financial results for its fiscal first quarter ended September 30, 2025. To listen to the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the "Ispire Technology Call." Date: Thursday, November 6, 2025Time: 8:00 am ETDial-In Nu

    11/4/25 4:05:00 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Ispire Technology Inc.

    SC 13G - Ispire Technology Inc. (0001948455) (Subject)

    7/12/24 5:00:02 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care